1. Generics Bulletin

IGBA Criticizes Export Restrictions

Supply Disruptions Are Counter-Productive During Coronavirus Crisis

 
• By Dave Wallace

National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.

Restrictions
Export Bans Have Been Slammed By The IGBA • Source: Shutterstock

Restrictions on pharmaceutical exports imposed by countries in the context of the coronavirus pandemic are “counter-productive in responding to a global public health crisis,” the International Generic and Biosimilar Medicines Association has warned.

At the start of March, India caused waves in the off-patent industry by imposing export restrictions on 13 active pharmaceutical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

Adalvo Changes Hands As EQT Takes Control

 
• By Dave Wallace

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

FTC’s Latest Effort To Dispute Improper Patent Listings Barely Made A Dent

 
• By Urtė Fultinavičiūtė

Trump’s FTC has carried on two legacies – trying to eliminate improper drug patent listings and making minimal impact on such efforts.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By Dave Wallace

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.